Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology
Pharmaceutical Business Review
The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers.
pharminent
September 2, 2026 (Last updated: September 2, 2026)
Pharmaceutical Business Review
The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers.